References
- Eaker E, Packard B, Wenger N, et al. Coronary heart disease in women. Administrative Summary on Coronary Heart Disease in Women Workshop. Bethesda: National Heart, Lung, and Blood Institute, 1986: 986.
- Blackburn H, Luepker R. Heart disease. In: Last J (ed). Preventive medicine and public health. New York: Medical Publishers, 1987: chap 33
- Oliver MF. Coronary heart disease in young women. In Oliver MF, ed. New York: Churchill Livingstone, 1978
- Gordon T, Kannel WB, Hjortland MC, et al. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 1978: 89(2): 157–61
- Perlman JA, Krauss RM, Ray R, et al. Smoking, oral contraceptives and other risk factors for atherosclerotic heart disease. In: Rosenberg MJ, ed. Smoking and reproductive health. New York: Praeger Medical, 1987
- Mazzone T, Jensen M, Chait A. Human arterial wall cells secrete factors that are chemotactic for monocytes. Proc Natl Acad Sci U S A 1983: 80(16): 5094–7
- Miller NE, Hammett F, Saltissi S, et al. Relation of angiographically defined coronary artery disease to plasma lipoprotein subtractions and apolipoproteins. Br Med J [Clin Res] 1981: 282(6278): 1741–4
- Gaspard UJ. Metabolic effects of oral contraceptives. Am J Obstet Gynecol 1987: 157(4 Pt 2): 1029–41
- Tikkanen MJ, Nikkila EA. Oral contraceptives and lipoprotein metabolism. J Reprod Med 1986: 31(9 Suppl): 898–905
- Bradley DD, Wingerd J, Peritti DB, et al. Serum high-density-Iipoprotein cholesterol in women using oral contraceptives, estrogens and progestins. N Engl J Med 1978: 299(1): 17–20
- Knopp RH, Walden CE, Wahl PW, et al. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency. J Clin Endocrinol Metab 1981: 53(6): 1123–32
- Dorflinger LJ. Relative potency of progestins used in oral contraceptives. Contraception 1985: 31(6): 557–70
- Wahl P, Walden C, Knopp R, et al. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 1983: 308(15): 862–7
- Larsson-Cohn U, Fahraeus L, Wallentin L, et al. Lipoprotein changes may be minimized by proper composition of a combined oral contraceptive. Fertil Steril 1981: 35(2): 172–9
- Wynn V, Niththyananthan R. The effect of progestins in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins. Am J Obstet Gynecol 1982: 142(6 Pt 2): 766–71
- Burkman RT, Robinson JC, Kruszon-Moran D, et al. Lipid and lipoprotein changes associated with oral contraceptive use: a randomized clinical trial. Obstet Gynecol 1988: 71(1): 33–8
- Vermeulen A, Thiery M. Metabolic effects of the triphasic oral contraceptive Trigynon. Contraception 1982: 26(5): 505–13
- Ellsworth HS, Ayerst RI, Harris JW, et al. Evaluation of a new triphasic oral contraceptive in private practice. Contraception 1986: 34(5): 435–42
- Percival-Smith RK, Morrison BJ, Sizto R, et al. The effect of triphasic and biphasic oral contraceptive preparations on HDL-cholesterol and LDL-cholesterol in young women. Contraception 1987: 35(2): 179–87
- Cullberg G, Samsioe G, Andersen RF, et al. Two oral contraceptives, efficacy, serum proteins, and lipid metabolism: a comparative multicentre study on a triphasic and a fixed dose combination. Contraception 1982: 26(3): 229–43
- Schif CP, Thomas CM, Demacker PN, et al. The influence of the triphasic pill and desogestrel-containing combination pill on some physical biochemical and hormonal parameters: a preliminary report. In: Rolland R, ed. Advances in fertility control and the treatment of sterility. Lancaster, PA: MTP Press, 1984: 61–70